JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 41 No. 11 1830-1835
© 2000 by Society of Nuclear Medicine
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Passchier, J.
Right arrow Articles by Vaalburg, W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Passchier, J.
Right arrow Articles by Vaalburg, W.

In Vivo Delineation of 5-HT1A Receptors in Human Brain with [18F]MPPF

Jan Passchier, Aren van Waarde, Remge M. Pieterman, Philip H. Elsinga, Jan Pruim, Harry N. Hendrikse, Antoon T.M. Willemsen and Willem Vaalburg

PET Center, Groningen University Hospital, Groningen; Groningen University Institute for Drug Exploration, Groningen, The Netherlands


Figure 1
View larger version (25K):
[in this window]
[in a new window]

 
FIGURE 1. Time–activity curves for several brain regions after intravenous injection of 79 MBq [18F]MPPF in single subject.

 

Figure 2
View larger version (91K):
[in this window]
[in a new window]

 
FIGURE 2. Comparison between distribution of [18F]MPPF and flow tracer [15O]H2O. For clarity, images were processed using gaussian filter (CAPP; Siemens/CTI). A = level of basal ganglia; B = level of medial temporal cortex.

 

Figure 3
View larger version (20K):
[in this window]
[in a new window]

 
FIGURE 3. Rate of metabolism of [18F]MPPF ({bigtriangleup} and dashed line represent fit) in single volunteer. Solid line represents metabolite-corrected arterial input function. Time interval from 0 to 10 min is shown in inset.

 

Figure 4
View larger version (14K):
[in this window]
[in a new window]

 
FIGURE 4. Radiochromatograms of [18F]MPPF-derived radioactivity in human plasma at 1, 5, and 40 min after injection. PM = polar metabolite.

 

Figure 5
View larger version (20K):
[in this window]
[in a new window]

 
FIGURE 5. Example of linear graphic analysis using Logan-Patlak fits. Slopes of fits represent the distribution volumes. ROI(T) refers to radioactivity in region of interest at time t. CER = cerebellum; Cp(t) = plasma radioactivity corrected for metabolites (23); {int}0T Cp(t)dt = integral of plasma radioactivity over time from time zero to time t; LTC = lateral temporal cortex; {int}0T ROI(t)dt = integral of radioactivity in region of interest over time from time zero to time t.

 

Figure 6
View larger version (16K):
[in this window]
[in a new window]

 
FIGURE 6. Correlation of distribution of [18F]MPPF in vivo with that of [3H]8-OH-2-(di-n-propylamino)tetralin in postmortem human brain (12). 1 = frontal cortex; 2 = cingulate cortex; 3 = insular cortex; 4 = medial temporal cortex (including hippocampal area).

 

Figure 7
View larger version (15K):
[in this window]
[in a new window]

 
FIGURE 7. Correlation of binding potentials (BP) of [18F]MPPF with those of [carbonyl-11C]WAY 100635 reported in literature (18,19). 1 = cingulate cortex; 2 = insular cortex; 3 = medial temporal cortex; 4 = frontal cortex; 5 = lateral temporal cortex.

 





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2000 by the Society of Nuclear Medicine.